Archive
Year
Volume(Issue)
Issues
Journal Article
Download
فارسی Version
Safety findings from FORWARD II: A Phase 1b study evaluating the folate receptor alpha (FRα )-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer
JOURNAL OF CLINICAL ONCOLOGY
Year:
Volume:
Issue:
Pages:
Citations:
Views:
Downloads:
more
View 51
Phase I study of ABBV-399, a c-Met antibody-drug conjugate (ADC), as monotherapy and in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC)
View 54
GCT1021-01, a firstinhuman, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors (NCT02988817)
View 76
Phase 1/2, multicenter, nonrandomized, open-label, multiple-dose first-in-human study of U3-1402 (anti-HER3 antibody drug conjugate) in subjects with HER3-positive metastatic breast cancer
View 66